



**NM DRUG OVERDOSE PREVENTION QUARTERLY MEASURES REPORT
FIRST QUARTER OF 2022 (2022Q1)**

**Substance Abuse Epidemiology Section
Prescription Drug Overdose Prevention Program
Injury and Behavioral Epidemiology Bureau
Epidemiology and Response Division**

This report is produced quarterly to track indicators related to drug overdose prevention. The indicators reported here allow for the tracking of three key interventions for prescription drug overdose: improving prescribing of controlled substances, increasing the availability of treatment for opioid dependence, and the increasing availability of naloxone in the community.

This report is based on calendar quarters: Q1 is January-March of the calendar year.



Data for this report were drawn from several sources:

1. The Prescription Monitoring Program (PMP) operated by the NM Board of Pharmacy, which collects data on every controlled substance prescription filled in New Mexico.
2. New Mexico Medicaid in the Human Services Department, for data on methadone treatment paid by Medicaid, and for data on claims paid for naloxone prescriptions at pharmacies.
3. The State Opioid Treatment Authority in the Human Services Department for data on methadone treatment programs operating in New Mexico.
4. The NM Department of Health Syringe Services Program for data on naloxone distributed via syringe exchange sites.
5. The Behavioral Health Services Division in the Human Services Department for data on naloxone distributed through Office of Substance Abuse Prevention programs.




Reports for 2020 Q2 and after reflect a changed definition of medication assisted treatment (MAT). The older definition defined MAT as buprenorphine/naloxone combination products only. The new definition has been applied to all quarters included in this report and includes all buprenorphine products except a couple of types indicated for the treatment of pain. Because MAT products are usually high-dose prescriptions and are counted separately from other opioids, this change has an effect on many of the indicators in this report.

Prior to 2020 Q4, a number of controlled substances were excluded from the analyses that are the basis of this report. These included the barbiturates and some miscellaneous controlled substances (notably testosterone and pregabalin). The inclusion of these drugs increased the number of controlled substance patients and providers reported, and increased the number of patients with multiple providers or pharmacies. Most other indicators were not affected.

I. New Mexico Prescription Monitoring Program (PMP) Measures



I. New Mexico Prescription Monitoring Program (PMP) Measures



I. New Mexico Prescription Monitoring Program (PMP) Measures

Totals

Year and Quarter	2021Q1	2021Q4	2022Q1	Quarterly % Change 2021Q4 vs 2022Q1	Quarterly % Change 2021Q1 vs 2022Q1
Total number of controlled substance patients	224,137	216,679	219,567	1.3%	-2.0%
Number of patients receiving opioids (excluding MAT)	120,421	114,325	114,783	0.4%	-4.7%
Number of opioid prescriptions filled (excluding MAT)	260,693	242,343	242,648	0.1%	-6.9%
Number of MAT buprenorphine prescriptions filled	28,974	28,033	28,793	2.7%	-0.6%
Number of high dose (>=90 MME/day) opioid prescriptions (excluding MAT)	23,786	21,056	20,375	-3.2%	-14.3%
Total MME of opioids filled - (excluding MAT)	192,944,809	175,622,906	172,332,425	-1.9%	-10.7%
Total MME/prescription-day	46	44	44	0.2%	-4.3%
Number of patients receiving benzodiazepines	74,373	68,125	68,633	0.7%	-7.7%
Number of benzodiazepine prescriptions filled	163,797	147,829	148,772	0.6%	-9.2%
Number of high-dose(>=40 DME/day) benzodiazepine prescriptions filled	26,879	23,118	22,995	-0.5%	-14.4%
Total DME of benzodiazepines filled	79,501,087	71,404,884	70,843,854	-0.8%	-10.9%
Total DME/patient	1,069	1,048	1,032	-1.5%	-3.4%

SOURCE OF DATA: NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance patients

MAT = Medication assisted treatment - the use of buprenorphine products indicated for treatment of opioid use disorder. Excludes products indicated for the treatment of pain.

MME = Morphine Milligram Equivalent; reference at http://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf

DME = Diazepam Milligram Equivalent; reference at <http://archinte.jamanetwork.com/article.aspx?articleid=217249>, 2004

I. New Mexico Prescription Monitoring Program (PMP) Measures

Number of Patients with:

Year and Quarter	2021Q1	2021Q4	2022Q1	Quarterly % Change 2021Q4 vs 2022Q1	Quarterly % Change 2021Q1 vs 2022Q1
High dose opioids (>=90 MME/day) (excluding MAT)	8,573	7,831	7,586	-3.1%	-11.5%
High dose benzodiazepines (>=40 DME/day)	11,901	10,140	10,193	0.5%	-14.4%
Opioids >=90 days and <90% of days in past 6 months (excluding MAT)	14,572	14,228	13,893	-2.4%	-4.7%
Opioids >=90% of days in past 6 months (excluding MAT)	27,608	25,520	25,102	-1.6%	-9.1%
Benzodiazepines >=90 days and <90% of days in past 6 months	17,448	16,431	16,190	-1.5%	-7.2%
Benzodiazepines >=90% of days in past 6 months	22,261	20,453	20,249	-1.0%	-9.0%
Overlapping prescriptions of opioids from different prescribers (>=10 days total overlap)	1,971	1,940	1,849	-4.7%	-6.2%
Overlapping prescriptions of benzodiazepines from different prescribers (>=10 days total overlap)	1,462	1,304	1,292	-0.9%	-11.6%
Concurrent opioid and benzodiazepines (>=10 days overlap)	12,568	11,612	11,272	-2.9%	-10.3%
High dose opioids (>=90 MME/day) plus benzodiazepines	1,908	1,677	1,630	-2.8%	-14.6%
Multiple prescribers and pharmacies: 4 or more prescribers or 4 or more pharmacies in 3 months	1,663	1,540	1,471	-4.5%	-11.5%
New Opioid Patients with at least 30 days of coverage in the past 3 months (excl MAT)	1,920	2,103	1,918	-8.8%	-0.1%
New Benzodiazepine Patients with at least 30 days of coverage in the past 3 months	3,267	3,047	3,117	2.3%	-4.6%

SOURCE OF DATA: NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance patients

I. New Mexico Prescription Monitoring Program (PMP) Measures


New Mexico Prescribers with at least 20 controlled substance patients:

Year and Quarter	2021Q1	2021Q4	2022Q1	Quarterly % Change 2021Q4 vs 2022Q1	Quarterly % Change 2021Q1 vs 2022Q1
Total active controlled substance prescribers	3,104	3,038	3,042	0.1%	-2.0%
Prescribers with at least 50% high dose of opioid prescriptions, excluding treatment prescribers	30	23	25	8.7%	-16.7%
Prescribers with at least 50% high dose of benzodiazepine prescriptions	111	87	86	-1.1%	-22.5%
Prescribers with at least 25% of patients having concurrent opioids and benzodiazepines	4	2	2	0.0%	-50.0%
Some PMP Use: Requested reports on at least 25% of patients estimated to require them	1,774	1,846	1,817	-1.6%	2.4%
Zero PMP Use: Requested no PMP reports on patients filling Controlled Substances	249	211	219	3.8%	-12.0%
Number of Patients with PMP reports requested by practitioners	385,674	400,459	421,518	5.3%	9.3%
% of Chronic opioid users with a PMP request in the past 3 months*	83.4%	82.8%	83.0%	0.3%	-0.4%
% of Chronic benzodiazepine users with a PMP request in the past 3 months*	62.5%	60.9%	61.8%	1.4%	-1.1%
% of New Opioid Patients with a PMP request in the past 3 months**	42.6%	46.9%	46.4%	-0.9%	9.0%
% of New Benzodiazepine Patients with a PMP request in the past 3 months**	45.3%	48.6%	47.7%	-1.8%	5.2%

*Chronic users are those with at least 90 days of coverage in six months.

**New patients are those with more than 4 days of coverage in the quarter and none in the prior quarter.

SOURCE OF DATA: NM Prescription Monitoring Program (PMP), NM Prescribers with at least 20 controlled substance patients



II. Medication Assisted Treatment (buprenorphine and methadone) Measures

Year and Quarter	2021Q1	2021Q4	2022Q1	Quarterly % Change 2021Q4 vs 2022Q1	Quarterly % Change 2021Q1 vs 2022Q1
Buprenorphine MAT prescribers with at least 10 treatment patients	230	236	255	8.1%	10.9%
Buprenorphine MAT patients (>=10 days)	8,189	8,241	8,397	1.9%	2.5%
Buprenorphine MAT prescriptions filled	28,974	28,033	28,793	2.7%	-0.6%
Total Practitioners with DATA Waiver	1,167	1,319	1,415	7.3%	21.3%
Nurse Practitioners and PAs with DATA Waiver	404	483	541	12.0%	33.9%

Medicaid Methadone Treatment

Number of distinct individuals with methadone claims paid by NM Medicaid	6,035	6,241	5,926	-5.0%	-1.8%
Number of distinct NM Medicaid providers of methadone	13	13	14	7.7%	7.7%

Methadone Treatment Programs by Survey Date	Mar 2021	Dec 2021	Mar 2022		
Number of Methadone Treatment Programs	21	21	21	0.0%	0.0%
Number of Methadone Treatment Patients in those Programs	7,235	7,335	7,377	0.6%	2.0%


DATA Waivered provider data are as of the last month of the quarter

Sources:

Buprenorphine MAT data: NM Prescription Monitoring Program

Methadone data: NM Human Services Department, State Opioid Treatment Authority; NM Medicaid

DATA Waivered providers: US DEA Diversion Control Division



III. Naloxone Distribution and Usage Measures

Year and Quarter	2021Q1	2021Q4	2022Q1	Quarterly % Change 2021Q4 vs 2022Q1	Quarterly % Change 2021Q1 vs 2022Q1
New Enrollments in NM State Government Naloxone Programs	1,925	3,468	3,833	10.5%	99.1%
Total Number of NM Naloxone Doses distributed*	8,808	16,796	12,770	-24.0%	45.0%
Total Number of NM Reported Reversals**	582	935	714	-23.6%	22.7%

Year and Quarter	2021Q1	2021Q4	2022Q1	Quarterly % Change 2021Q4 vs 2022Q1	Quarterly % Change 2021Q1 vs 2022Q1
Pharmacies Presenting Medicaid Naloxone Claims+	251	254	247	-2.8%	-1.6%
Number of Medicaid Naloxone Claims Processed	4,948	3,700	4,016	8.5%	-18.8%

*Some naloxone doses were given to organizations and may not have been distributed in that quarter.

**Reported Reversals are not necessarily individual level data, as one person could have overdosed and been reversed more than once. Data on reversals are combined across several agencies and programs, and the definition of a reversal may vary.

+An outpatient pharmacy could present claims in more than one quarter. The total number was obtained by counting each pharmacy once. There were 286 outpatient Pharmacies with a NM address in 2019 according to the Board of Pharmacy.

Sources: NM DOH Programs; NM HSD/BHSD Programs; NM Medicaid

